{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:20:20Z","timestamp":1789600820295,"version":"build-2803163510"},"reference-count":51,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272200800039C"],"award-info":[{"award-number":["HHSN272200800039C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01-AI061142"],"award-info":[{"award-number":["U01-AI061142"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DMTC Ltd","award":["JEV-Advax Phase 1"],"award-info":[{"award-number":["JEV-Advax Phase 1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>ccJE+Advax is an inactivated cell culture Japanese encephalitis (JE) vaccine formulated with Advax, a novel polysaccharide adjuvant based on delta inulin. This vaccine has previously shown promise in murine and equine studies and the current study sought to better understand its mechanism of action and assess the feasibility of single dose vaccine protection. Mice immunised with ccJE+Advax had higher serum neutralisation titres than those immunised with ccJE alone or with alum adjuvant. ccJE+Advax induced extraordinarily broad cross-neutralising antibodies against multiple flaviviruses including West Nile virus (WNV), Murray Valley encephalitis virus (MVEV), St Louis encephalitis virus (SLEV) and Dengue virus-1 and -2 (DENV-1 and -2). Notably, the DENV-2 cross-neutralising antibodies from ccJE+Advax immunised mice uniquely had no DENV-2 antibody-dependent infection enhancement (ADIE) activity, in contrast to high ADIE activity seen with DENV-1 cross-reactive antibodies induced by mbJE or ccJE alone or with alum adjuvant. JEV-stimulated splenocytes from ccJE+Advax immunised mice showed increased IL-17 and IFN-\u03b3 production, consistent with a mixed Th1 and Th17 response, whereas ccJE-alum was associated with production of mainly Th2 cytokines. In a mouse lethal challenge study against highly virulent JaTH160 JEV strain, ccJE+Advax conferred complete protection in a two-dose schedule with 50 ng of vaccine antigen and near complete protection after a single 200 ng dose of vaccine antigen. There is an ongoing lack of human vaccines against particular flaviviruses, including WNV, SLEV and MVEV. Given its ability to provide single-dose JEV protection and induce broadly neutralising antibodies devoid of ADIE activity, ccJE+Advax vaccine could be useful in situations where rapid protection is desirable, e.g., during a local outbreak or for use in travellers or armies requiring rapid deployment to JEV endemic regions.<\/jats:p>","DOI":"10.3390\/vaccines9111235","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T21:42:05Z","timestamp":1635198125000},"page":"1235","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Advax-Adjuvanted Inactivated Cell-Culture Derived Japanese Encephalitis Vaccine Induces Broadly Neutralising Anti-Flavivirus Antibodies, Robust Cellular Immunity and Provides Single Dose Protection"],"prefix":"10.3390","volume":"9","author":[{"given":"Tomoyoshi","family":"Komiya","sequence":"first","affiliation":[{"name":"Faculty of Health and Medical Sciences, Hokuriku University, Kanazawa 920-1180, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-8621","authenticated-orcid":false,"given":"Yoshikazu","family":"Honda-Okubo","sequence":"additional","affiliation":[{"name":"Vaxine Pty Ltd., Adelaide 5046, Australia"},{"name":"Department of Endocrinology, College of Medicine and Public Health, Flinders University, Adelaide 5042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Vaxine Pty Ltd., Adelaide 5046, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-5245","authenticated-orcid":false,"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[{"name":"Vaxine Pty Ltd., Adelaide 5046, Australia"},{"name":"Department of Endocrinology, College of Medicine and Public Health, Flinders University, Adelaide 5042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid1501.080311","article-title":"Past, present, and future of Japanese encephalitis","volume":"15","author":"Erlanger","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: A systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull. World Health Organ."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Connor, B., and Bunn, W.B. (2017). The changing epidemiology of Japanese encephalitis and New data: The implications for New recommendations for Japanese encephalitis vaccine. Trop. Dis. Travel Med. Vaccines, 3.","DOI":"10.1186\/s40794-017-0057-x"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1056\/NEJM198809083191004","article-title":"Protection against Japanese encephalitis by inactivated vaccines","volume":"319","author":"Hoke","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/BC.2008.062","article-title":"Japanese encephalitis vaccines\u2013needs, flaws and achievements","volume":"389","author":"Tauber","year":"2008","journal-title":"Biol Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1080\/21645515.2017.1285472","article-title":"Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease","volume":"13","author":"Hegde","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1099\/0022-1317-76-2-409","article-title":"Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14","volume":"76","author":"Ni","year":"1995","journal-title":"J. Gen. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4269\/ajtmh.14-0427","article-title":"Genetic and phenotypic properties of vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice","volume":"92","author":"Gromowski","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0042-6822(90)90519-W","article-title":"Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA-14-14-2","volume":"177","author":"Nitayaphan","year":"1990","journal-title":"Virology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: A non-inferiority, phase III, randomised controlled trial","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Le Flohic, G., Porphyre, V., Barbazan, P., and Gonzalez, J.-P. (2013). Review of climate, landscape, and viral genetics as drivers of the Japanese encephalitis virus ecology. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002208"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Rathore, A.P.S., and St John, A.L. (2020). Cross-Reactive Immunity Among Flaviviruses. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00334"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.vaccine.2007.10.055","article-title":"Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus","volume":"26","author":"Martina","year":"2008","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1016\/S0264-410X(03)00507-3","article-title":"Partial protective effect of inactivated Japanese encephalitis vaccine on lethal West Nile virus infection in mice","volume":"21","author":"Takasaki","year":"2003","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0264-410X(02)00743-0","article-title":"Cross-protective and infection-enhancing immunity in mice vaccinated against flaviviruses belonging to the Japanese encephalitis virus serocomplex","volume":"21","author":"Lobigs","year":"2003","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1128\/JVI.02273-08","article-title":"Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus","volume":"83","author":"Lobigs","year":"2009","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1099\/vir.0.18980-0","article-title":"Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice","volume":"84","author":"Wallace","year":"2003","journal-title":"J. Gen. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/(SICI)1096-9071(200006)61:2<259::AID-JMV13>3.0.CO;2-M","article-title":"Immunisation with gamma globulin to Murray Valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against Australian encephalitis: Evaluation in a mouse model","volume":"61","author":"Broom","year":"2000","journal-title":"J. Med Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1995-7645(14)60007-9","article-title":"Co-positivity of anti-dengue virus and anti-Japanese encephalitis virus IgM in endemic area: Co-infection or cross reactivity?","volume":"7","author":"Singh","year":"2014","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.3390\/v3122374","article-title":"The human antibody response to dengue virus infection","volume":"3","author":"Wahala","year":"2011","journal-title":"Viruses"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1099\/0022-1317-77-4-705","article-title":"Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitis virus by adoptively transferred virus-specific cytotoxic T lymphocytes: Requirement for L3T4+ T cells","volume":"77","author":"Ravi","year":"1996","journal-title":"J. Gen. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0264-410X(99)00180-2","article-title":"Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese Encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies","volume":"18","author":"Ashok","year":"1999","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1086\/381768","article-title":"Impaired T helper 1 function of nonstructural protein 3-specific T cells in Japanese patients with encephalitis with neurological sequelae","volume":"189","author":"Kumar","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax\u2122, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1099\/vir.0.019190-0","article-title":"An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses","volume":"91","author":"Lobigs","year":"2010","journal-title":"J. Gen. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hayasaka, D., Shirai, K., Aoki, K., Nagata, N., Simantini, D.S., Kitaura, K., Takamatsu, Y., Gould, E., Suzuki, R., and Morita, K. (2013). TNF-\u03b1 acts as an immunoregulator in the mouse brain by reducing the incidence of severe disease following Japanese encephalitis virus infection. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071643"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1128\/JVI.76.7.3202-3211.2002","article-title":"Lack of both Fas ligand and perforin protects from flavivirus-mediated encephalitis in mice","volume":"76","author":"Lee","year":"2002","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1016\/j.vaccine.2008.04.076","article-title":"Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium","volume":"26","author":"Toriniwa","year":"2008","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Moi, M.L., Lim, C.-K., Chua, K.B., Takasaki, T., and Kurane, I. (2012). Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using Fc\u03b3R-expressing cells. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001536"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1016\/j.vaccine.2011.06.062","article-title":"Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(\u00ae)) induced neutralizing antibody titers","volume":"29","author":"Klade","year":"2011","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4049\/jimmunol.140.4.1022","article-title":"IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses","volume":"140","author":"Finkelman","year":"1988","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1126\/science.8456300","article-title":"Multiple defects of immune cell function in mice with disrupted interferon-gamma genes","volume":"259","author":"Dalton","year":"1993","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(18)32560-1","article-title":"Dengue","volume":"393","author":"Ooi","year":"2019","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Saito, Y., Moi, M.L., Takeshita, N., Lim, C.-K., Shiba, H., Hosono, K., Saijo, M., Kurane, I., and Takasaki, T. (2016). Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1873-8"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/eji.201243152","article-title":"Cytolytic effector pathways and IFN-\u03b3 help protect against J apanese encephalitis","volume":"43","author":"Larena","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ebiom.2016.11.015","article-title":"Advax, a delta inulin microparticle, potentiates in-built adjuvant property of co-administered vaccines","volume":"15","author":"Hayashi","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and safety of Advax\u2122, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2016.05.071","article-title":"Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax\u2122 delta inulin adjuvant","volume":"34","author":"Gordon","year":"2016","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1016\/j.vaccine.2012.06.009","article-title":"Randomized clinical trial of immunogenicity and safety of a recombinant H1N1\/2009 pandemic influenza vaccine containing Advax\u2122 polysaccharide adjuvant","volume":"30","author":"Gordon","year":"2012","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1016\/j.vaccine.2008.08.046","article-title":"Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaci.2019.03.035","article-title":"Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy","volume":"144","author":"Heddle","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1128\/JVI.00480-13","article-title":"An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody","volume":"87","author":"Petrovsky","year":"2013","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1099\/jmm.0.038943-0","article-title":"Alum adjuvant: Some of the tricks of the oldest adjuvant","volume":"61","author":"Kool","year":"2012","journal-title":"J. Med. Microbiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4269\/ajtmh.2002.66.115","article-title":"absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines","volume":"66","author":"Putnak","year":"2002","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4269\/ajtmh.2008.78.999","article-title":"Failure of Japanese encephalitis vaccine and infection in inducing neutralizing antibodies against West Nile virus, People\u2019s Republic of China","volume":"78","author":"Tang","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/infdis\/161.5.878","article-title":"Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants","volume":"161","author":"Poland","year":"1990","journal-title":"J. Infect. Dis."},{"key":"ref_47","unstructured":"Plotkin, S.A., Orenstein, W.A., and Offit, P.A. (2008). Japanese encephalitis vaccines. Vaccines, Elsevier. [6th ed.]."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1016\/S0264-410X(03)00506-1","article-title":"Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine","volume":"21","author":"Kuzuhara","year":"2003","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tmaid.2018.03.003","article-title":"Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO\u00ae, JESPECT\u00ae) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study","volume":"22","author":"Jelinek","year":"2018","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00705-012-1337-4","article-title":"The contribution of rodent models to the pathological assessment of flaviviral infections of the central nervous system","volume":"157","author":"Clark","year":"2012","journal-title":"Arch. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/0300985810372507","article-title":"Flavivirus encephalitis: Pathological aspects of mouse and other animal models","volume":"47","author":"Kimura","year":"2010","journal-title":"Vet. Pathol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/11\/1235\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:21:57Z","timestamp":1760167317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/11\/1235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,23]]},"references-count":51,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["vaccines9111235"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9111235","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202110.0034.v1","asserted-by":"object"}]},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,23]]}}}